Clovis Oncology

Clovis Oncology is a commercial-stage biotechnology company headquartered in Boulder, Colorado. Founded in 2009, the company employs 192 people and generated $145 million in revenue. Clovis Oncology is listed on the NASDAQ stock exchange under the ticker symbol CLVS. Clovis Oncology focuses on acquiring, developing, and commercializing cancer treatments. They specialize in precision medicine, aiming to deliver the right drug to the right patient at the right time. Their product development programs typically target specific subsets of cancer, and they collaborate with partners to develop diagnostic tools to identify patients who would most benefit from their treatments. The company's management team possesses extensive experience in developing novel cancer therapies and shares a dedication to improving the lives of cancer patients. Through strategic partnerships, Clovis Oncology leverages diverse technologies to expedite regulatory approvals and support global commercialization efforts. For more information, including additional office locations in the United States and Europe, please visit their website at clovisoncology.com.